Sign inJoin waitlistJoin the waitlist

Jonathan Wesley Riess

Hematology & Oncology · Regents of the Univ of Ca

Credentials: · ·

History

Stanford University School of Medicine
2009–2011
UC San Francisco
2006–2009
UC San Francisco
Until 2007
Robert Wood Johnson Medical School
2006

Research

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 1,255 citations
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Journal of Clinical Oncology · 2021 · 978 citations
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 922 citations

David Gandara
41 papers · 5 as a fellow
Heather Wakelee
33 papers
Joel Neal
27 papers · 1 as a fellow
Matthew Gubens
17 papers
Primo Lara
17 papers
Xiuning Le
15 papers
KK
Karen Kelly
14 papers
Collin Blakely
12 papers
Sarah Goldberg
12 papers
Sukhmani Padda
12 papers
Billy Loo
11 papers
Dara Aisner
11 papers

Grants

University of California and UT Southwestern D-PDTC
National Cancer Institute · U54
PI · $4.7M · University of California at Davis
2023–2028
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
National Cancer Institute · UM1
PI · $1.9M · Beckman Research Institute/City of Hope
2014–2027
A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients
National Cancer Institute · R01
PI · $1.8M · Sloan-Kettering Inst Can Research
2021–2026

Clinical trials

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
Principal investigator · Not yet recruiting · Phase 1
Jonathan Riess
2024–2026
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Principal investigator · Completed · Phase 2
IO Biotech
2022–2026
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2020–2026
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2019–2024